Comments
Loading...
Vertex Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:VRTX | Benzinga
Vertex Pharmaceuticals Inc has a consensus price target of $511.08 based on the ratings of 31 analysts. The high is $586 issued by UBS on November 5, 2024. The low is $420 issued by RBC Capital on April 1, 2025. The 3 most-recent analyst ratings were released by Cantor Fitzgerald, RBC Capital, and B of A Securities on April 22, 2025, April 1, 2025, and March 31, 2025, respectively. With an average price target of $507.33 between Cantor Fitzgerald, RBC Capital, and B of A Securities, there's an implied 0.99% upside for Vertex Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
RBC Capital
B of A Securities
Canaccord Genuity
Truist Securities
1calculated from analyst ratings
Analyst Ratings for Vertex Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/22/2025 | Buy Now | 6.5% | Cantor Fitzgerald | Carter Gould59% | → $535 | Assumes | → Overweight | Get Alert |
| 04/01/2025 | Buy Now | -16.39% | RBC Capital | Brian Abrahams49% | $408 → $420 | Maintains | Sector Perform | Get Alert |
| 03/31/2025 | Buy Now | 12.87% | B of A Securities | Ying Huang64% | $555 → $567 | Maintains | Buy | Get Alert |
| 02/20/2025 | Buy Now | -18.78% | RBC Capital | Brian Abrahams49% | $407 → $408 | Maintains | Sector Perform | Get Alert |
| 02/12/2025 | Buy Now | -15.6% | Canaccord Genuity | Whitney Ijem49% | $408 → $424 | Upgrade | Sell → Hold | Get Alert |
| 02/11/2025 | Buy Now | 3.51% | Truist Securities | Joon Lee77% | $460 → $520 | Maintains | Buy | Get Alert |
| 02/11/2025 | Buy Now | -18.98% | RBC Capital | Brian Abrahams49% | $402 → $407 | Maintains | Sector Perform | Get Alert |
| 02/11/2025 | Buy Now | -10.42% | Scotiabank | Greg Harrison46% | $433 → $450 | Maintains | Sector Perform | Get Alert |
| 02/11/2025 | Buy Now | -4.45% | Cantor Fitzgerald | Olivia Brayer58% | $480 → $480 | Reiterates | Overweight → Overweight | Get Alert |
| 02/11/2025 | Buy Now | -7.04% | Barclays | Gena Wang50% | $435 → $467 | Maintains | Equal-Weight | Get Alert |
| 02/11/2025 | Buy Now | 9.49% | HC Wainwright & Co. | Andrew Fein57% | $550 → $550 | Reiterates | Buy → Buy | Get Alert |
| 02/11/2025 | Buy Now | -8.63% | Morgan Stanley | Matthew Harrison61% | $450 → $459 | Maintains | Equal-Weight | Get Alert |
| 02/11/2025 | Buy Now | — | Needham | Joseph Stringer52% | — | Reiterates | Hold → Hold | Get Alert |
| 01/31/2025 | Buy Now | -4.45% | Cantor Fitzgerald | Olivia Brayer58% | $480 → $480 | Reiterates | Overweight → Overweight | Get Alert |
| 01/31/2025 | Buy Now | -13.81% | Scotiabank | Greg Harrison46% | $430 → $433 | Maintains | Sector Perform | Get Alert |
| 01/31/2025 | Buy Now | 9.49% | HC Wainwright & Co. | Andrew Fein57% | $535 → $550 | Maintains | Buy | Get Alert |
| 01/31/2025 | Buy Now | — | Needham | Joseph Stringer52% | — | Reiterates | Hold → Hold | Get Alert |
| 01/30/2025 | Buy Now | -8.43% | Wells Fargo | Mohit Bansal71% | $460 → $460 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 01/27/2025 | Buy Now | 6.1% | Piper Sandler | Christopher Raymond55% | $535 → $533 | Maintains | Overweight | Get Alert |
| 01/24/2025 | Buy Now | -4.45% | Cantor Fitzgerald | Olivia Brayer58% | $480 → $480 | Reiterates | Overweight → Overweight | Get Alert |
| 01/10/2025 | Buy Now | -8.43% | Wells Fargo | Mohit Bansal71% | $555 → $460 | Maintains | Overweight | Get Alert |
| 12/23/2024 | Buy Now | -8.43% | Truist Securities | Joon Lee77% | $550 → $460 | Maintains | Buy | Get Alert |
| 12/23/2024 | Buy Now | -14.4% | Scotiabank | Greg Harrison46% | $426 → $430 | Maintains | Sector Perform | Get Alert |
| 12/23/2024 | Buy Now | -0.47% | JP Morgan | Jessica Fye65% | $503 → $500 | Maintains | Overweight | Get Alert |
| 12/20/2024 | Buy Now | -16.79% | Barclays | Gena Wang50% | $509 → $418 | Maintains | Equal-Weight | Get Alert |
| 12/20/2024 | Buy Now | 3.51% | BMO Capital | Evan Seigerman64% | $566 → $520 | Maintains | Outperform | Get Alert |
| 12/20/2024 | Buy Now | — | Needham | Joseph Stringer52% | — | Reiterates | Hold → Hold | Get Alert |
| 12/20/2024 | Buy Now | 6.5% | HC Wainwright & Co. | Andrew Fein57% | $600 → $535 | Maintains | Buy | Get Alert |
| 12/19/2024 | Buy Now | 3.91% | B of A Securities | Ying Huang64% | $545 → $522 | Maintains | Buy | Get Alert |
| 12/16/2024 | Buy Now | -1.66% | Stifel | Paul Matteis42% | $490 → $494 | Maintains | Hold | Get Alert |
| 12/09/2024 | Buy Now | 9.49% | Jefferies | Michael Yee56% | $500 → $550 | Upgrade | Hold → Buy | Get Alert |
| 11/14/2024 | Buy Now | 14.46% | Citigroup | Geoff Meacham62% | → $575 | Initiates | → Buy | Get Alert |
| 11/06/2024 | Buy Now | -18.78% | Canaccord Genuity | Whitney Ijem49% | $361 → $408 | Maintains | Sell | Get Alert |
| 11/05/2024 | Buy Now | -3.25% | Scotiabank | Greg Harrison46% | $480 → $486 | Maintains | Sector Perform | Get Alert |
| 11/05/2024 | Buy Now | 16.65% | UBS | Colin Bristow40% | $562 → $586 | Maintains | Buy | Get Alert |
| 11/05/2024 | Buy Now | -4.45% | Cantor Fitzgerald | Olivia Brayer58% | $480 → $480 | Reiterates | Overweight → Overweight | Get Alert |
| 11/05/2024 | Buy Now | -10.22% | RBC Capital | Brian Abrahams49% | $437 → $451 | Maintains | Sector Perform | Get Alert |
| 11/05/2024 | Buy Now | 0.13% | JP Morgan | Jessica Fye65% | $510 → $503 | Maintains | Overweight | Get Alert |
| 11/05/2024 | Buy Now | -5.25% | Morgan Stanley | Matthew Harrison61% | $473 → $476 | Maintains | Equal-Weight | Get Alert |
| 10/30/2024 | Buy Now | 7.49% | Oppenheimer | Hartaj Singh47% | $550 → $540 | Maintains | Outperform | Get Alert |
| 10/21/2024 | Buy Now | 19.44% | HC Wainwright & Co. | Andrew Fein57% | $600 → $600 | Reiterates | Buy → Buy | Get Alert |
| 10/17/2024 | Buy Now | 11.87% | UBS | Colin Bristow40% | $477 → $562 | Maintains | Buy | Get Alert |
| 10/16/2024 | Buy Now | -4.45% | Scotiabank | Greg Harrison46% | → $480 | Initiates | → Sector Perform | Get Alert |
| 10/14/2024 | Buy Now | 7.69% | B of A Securities | Ying Huang64% | $550 → $541 | Maintains | Buy | Get Alert |
| 10/10/2024 | Buy Now | — | Raymond James | Danielle Brill42% | — | Reinstates | → Market Perform | Get Alert |
| 10/09/2024 | Buy Now | -13.01% | RBC Capital | Brian Abrahams49% | $425 → $437 | Maintains | Sector Perform | Get Alert |
| 10/08/2024 | Buy Now | -4.45% | Cantor Fitzgerald | Olivia Brayer58% | $480 → $480 | Reiterates | Overweight → Overweight | Get Alert |
| 10/04/2024 | Buy Now | -15.4% | RBC Capital | Brian Abrahams49% | $431 → $425 | Maintains | Sector Perform | Get Alert |
| 10/01/2024 | Buy Now | -5.64% | Morgan Stanley | Matthew Harrison61% | $462 → $474 | Maintains | Equal-Weight | Get Alert |
| 09/19/2024 | Buy Now | -14.2% | RBC Capital | Brian Abrahams49% | $431 → $431 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 08/05/2024 | Buy Now | 19.44% | HC Wainwright & Co. | Andrew Fein57% | $500 → $600 | Maintains | Buy | Get Alert |
| 08/05/2024 | Buy Now | 9.49% | Oppenheimer | Hartaj Singh47% | $500 → $550 | Maintains | Outperform | Get Alert |
| 08/05/2024 | Buy Now | 1.52% | JP Morgan | Jessica Fye65% | $505 → $510 | Maintains | Overweight | Get Alert |
| 08/05/2024 | Buy Now | 9.49% | Truist Securities | Joon Lee77% | $508 → $550 | Reiterates | Buy → Buy | Get Alert |
| 08/05/2024 | Buy Now | 1.32% | Barclays | Gena Wang50% | $472 → $509 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 08/02/2024 | Buy Now | 11.08% | Guggenheim | Debjit Chattopadhyay51% | $450 → $558 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | -4.45% | Cantor Fitzgerald | Olivia Brayer58% | $480 → $480 | Reiterates | Overweight → Overweight | Get Alert |
| 08/02/2024 | Buy Now | 6.5% | Piper Sandler | Christopher Raymond55% | $500 → $535 | Maintains | Overweight | Get Alert |
| 07/31/2024 | Buy Now | -25.15% | Canaccord Genuity | Whitney Ijem49% | $371 → $376 | Maintains | Sell | Get Alert |
| 07/26/2024 | Buy Now | — | Needham | Joseph Stringer52% | — | Reiterates | → Hold | Get Alert |
| 07/23/2024 | Buy Now | -0.47% | TD Cowen | Phil Nadeau68% | $450 → $500 | Maintains | Buy | Get Alert |
| 07/22/2024 | Buy Now | -4.45% | Cantor Fitzgerald | Olivia Brayer58% | $440 → $480 | Maintains | Overweight | Get Alert |
| 07/19/2024 | Buy Now | -0.47% | HC Wainwright & Co. | Andrew Fein57% | $462 → $500 | Maintains | Buy | Get Alert |
| 07/11/2024 | Buy Now | -9.43% | Morgan Stanley | Matthew Harrison61% | $402 → $455 | Maintains | Equal-Weight | Get Alert |
| 06/27/2024 | Buy Now | 8.49% | Redburn Atlantic | Steve Chesney56% | → $545 | Initiates | → Buy | Get Alert |
| 06/24/2024 | Buy Now | 10.48% | Wells Fargo | Mohit Bansal71% | $540 → $555 | Maintains | Overweight | Get Alert |
| 06/17/2024 | Buy Now | 9.49% | Argus Research | Jasper Hellweg70% | $465 → $550 | Maintains | Buy | Get Alert |
| 06/11/2024 | Buy Now | -16.19% | RBC Capital | Brian Abrahams49% | $424 → $421 | Maintains | Sector Perform | Get Alert |
| 06/04/2024 | Buy Now | -15.6% | RBC Capital | Brian Abrahams49% | $424 → $424 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 05/31/2024 | Buy Now | -0.47% | BMO Capital | Evan Seigerman64% | $480 → $500 | Maintains | Outperform | Get Alert |
| 05/07/2024 | Buy Now | -8.03% | HC Wainwright & Co. | Andrew Fein57% | $462 → $462 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2024 | Buy Now | -15.6% | RBC Capital | Brian Abrahams49% | $417 → $424 | Maintains | Sector Perform | Get Alert |
| 05/07/2024 | Buy Now | -9.23% | Piper Sandler | Christopher Raymond55% | $450 → $456 | Maintains | Overweight | Get Alert |
| 05/07/2024 | Buy Now | — | Needham | Joseph Stringer52% | — | Reiterates | → Hold | Get Alert |
| 04/18/2024 | Buy Now | -10.42% | Guggenheim | Debjit Chattopadhyay51% | $445 → $450 | Maintains | Buy | Get Alert |
| 04/17/2024 | Buy Now | -7.24% | UBS | Colin Bristow40% | $498 → $466 | Maintains | Buy | Get Alert |
| 04/15/2024 | Buy Now | -0.47% | Oppenheimer | Hartaj Singh47% | → $500 | Maintains | Outperform | Get Alert |
| 04/12/2024 | Buy Now | -26.15% | Canaccord Genuity | Whitney Ijem49% | $371 → $371 | Maintains | Sell | Get Alert |
| 04/11/2024 | Buy Now | -8.03% | HC Wainwright & Co. | Andrew Fein57% | $457 → $462 | Maintains | Buy | Get Alert |
| 04/11/2024 | Buy Now | -12.81% | Evercore ISI Group | Liisa Bayko71% | → $438 | Upgrade | In-Line → Outperform | Get Alert |
| 02/20/2024 | Buy Now | -12.41% | Cantor Fitzgerald | Olivia Brayer58% | $440 → $440 | Reiterates | Overweight → Overweight | Get Alert |
| 02/15/2024 | Buy Now | — | Wolfe Research | Andy Chen42% | — | Initiates | → Outperform | Get Alert |
| 02/06/2024 | Buy Now | -12.41% | Cantor Fitzgerald | Olivia Brayer58% | $440 → $440 | Reiterates | Overweight → Overweight | Get Alert |
| 02/06/2024 | Buy Now | -10.42% | JP Morgan | Jessica Fye65% | $438 → $450 | Maintains | Overweight | Get Alert |
| 02/06/2024 | Buy Now | 7.49% | Wells Fargo | Mohit Bansal71% | $500 → $540 | Maintains | Overweight | Get Alert |
| 02/06/2024 | Buy Now | -16.39% | RBC Capital | Brian Abrahams49% | $397 → $420 | Maintains | Sector Perform | Get Alert |
| 02/06/2024 | Buy Now | -6.04% | Barclays | Gena Wang50% | $446 → $472 | Maintains | Overweight | Get Alert |
| 02/06/2024 | Buy Now | -12.81% | Evercore ISI Group | Liisa Bayko71% | $436 → $438 | Downgrade | Outperform → In-Line | Get Alert |
| 02/06/2024 | Buy Now | -9.03% | HC Wainwright & Co. | Andrew Fein57% | $397 → $457 | Maintains | Buy | Get Alert |
| 02/02/2024 | Buy Now | — | Bernstein | William Pickering39% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 02/01/2024 | Buy Now | -12.81% | JP Morgan | Jessica Fye65% | $390 → $438 | Maintains | Overweight | Get Alert |
| 01/31/2024 | Buy Now | 1.12% | Truist Securities | Robyn Karnauskas54% | $456 → $508 | Maintains | Buy | Get Alert |
| 01/31/2024 | Buy Now | 11.28% | Goldman Sachs | Salveen Richter52% | $442 → $559 | Maintains | Buy | Get Alert |
| 01/31/2024 | Buy Now | — | Maxim Group | Naz Rahman27% | — | Downgrade | Buy → Hold | Get Alert |
| 01/24/2024 | Buy Now | -12.41% | Cantor Fitzgerald | Olivia Brayer58% | $415 → $440 | Maintains | Overweight | Get Alert |
| 01/24/2024 | Buy Now | -24.55% | Canaccord Genuity | Whitney Ijem49% | $332 → $379 | Downgrade | Hold → Sell | Get Alert |
| 01/12/2024 | Buy Now | -17.39% | Cantor Fitzgerald | Olivia Brayer58% | $415 → $415 | Reiterates | Overweight → Overweight | Get Alert |
| 01/09/2024 | Buy Now | -17.39% | Cantor Fitzgerald | Olivia Brayer58% | $415 → $415 | Reiterates | Overweight → Overweight | Get Alert |
| 12/14/2023 | Buy Now | -24.36% | Cantor Fitzgerald | Olivia Brayer58% | $380 → $380 | Reiterates | Overweight → Overweight | Get Alert |
| 12/14/2023 | Buy Now | -24.55% | RBC Capital | Brian Abrahams49% | $347 → $379 | Maintains | Sector Perform | Get Alert |
FAQ
What is the target price for Vertex Pharmaceuticals (VRTX) stock?
The latest price target for Vertex Pharmaceuticals (NASDAQ:VRTX) was reported by Cantor Fitzgerald on April 22, 2025. The analyst firm set a price target for $535.00 expecting VRTX to rise to within 12 months (a possible 6.50% upside). 74 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Vertex Pharmaceuticals (VRTX)?
The latest analyst rating for Vertex Pharmaceuticals (NASDAQ:VRTX) was provided by Cantor Fitzgerald, and Vertex Pharmaceuticals their overweight rating.
When was the last upgrade for Vertex Pharmaceuticals (VRTX)?
The last upgrade for Vertex Pharmaceuticals Inc happened on February 12, 2025 when Canaccord Genuity raised their price target to $424. Canaccord Genuity previously had a sell for Vertex Pharmaceuticals Inc.
When was the last downgrade for Vertex Pharmaceuticals (VRTX)?
The last downgrade for Vertex Pharmaceuticals Inc happened on January 30, 2025 when Wells Fargo changed their price target from $460 to $460 for Vertex Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Vertex Pharmaceuticals (VRTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vertex Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vertex Pharmaceuticals was filed on April 22, 2025 so you should expect the next rating to be made available sometime around April 22, 2026.
Is the Analyst Rating Vertex Pharmaceuticals (VRTX) correct?
While ratings are subjective and will change, the latest Vertex Pharmaceuticals (VRTX) rating was a with a price target of $0.00 to $535.00. The current price Vertex Pharmaceuticals (VRTX) is trading at is $502.35, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
